References
- Biosimilar and interchangeable products. [cited 2019 Apr 26]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products.
- Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016;44(4):257–266.
- Gonczi L, Ilias A, Kurti Z, et al. Biosimilars in IBD: will it benefit to patients, physicians or the health care system? Curr Pharm Des. 2019;25(1):13–18.
- Guideline on similar biological medicinal products. [cited 2019 Apr 26]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf
- Argollo M, Fiorino G, Gilardi D, et al. Biosimilars of adalimumab in IBD: are we ready for that? Curr Pharm Des. 2019;25(1):7–12.
- Ben-Horin S, Vande Casteele N, Schreiber S, et al. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14(12):1685–1696.
- Lee C, Jeong M, Lee JJ, et al. Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®. MAbs. 2017;9(6):968–977.
- Bandyopadhyay S, Mahajan M, Mehta T, et al. Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197. Biosimilar. 2014;5:1–18.
- Kay J. Editorial: biosimilars: new or Déjà Vu? Arthritis Rheumatol. 2016;68(5):1049–1052.
- Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. MAbs. 2014;6(5):1163–1177.
- Remsima Assessment Report (EMA/CHMP/589317/2013). European medicines agency. [cited 2019 Nov 20]. https://www.ema.europa.eu/en/documents/assessment-report/remsima-epar-public-assessment-report_en.pdf
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014; [cited 2019 Jul 9]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf
- Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. 2012; [cited 2019 Jul 8]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf
- Lim KJ, Lee SJ, Kim S, et al. Comparable immune function inhibition by the infliximab biosimilar CT-P13: implications for treatment of inflammatory bowel disease. J Crohns Colitis. 2017;11(5):593–602.
- Vos AC, Wildenberg ME, Duijvestein M, et al. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology. 2011;140(1):221–230.
- Dörner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11(12):713–724.
- Assay development and validation for immunogenicity testing of therapeutic protein products. 2016; [cited 2019 May 22]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assay-development-and-validation-immunogenicity-testing-therapeutic-protein-products
- Guideline on Immunogenicity assessment of therapeutic proteins. [cited 2019 May 21]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf
- Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65(7):1132–1138.
- Reinisch W, Jahnsen J, Schreibe S, et al. Evaluation of the cross-reactivity of antidrug antibodies to CT-P13 and infliximab reference product (Remicade): an analysis using immunoassays tagged with both agents. BioDrugs. 2017;31(3):223–237.
- Fiorino G, Ruiz-Argüello MB, Maguregui A, et al. Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(3):601–606.
- Magro F, Rocha C, Vieira AI, et al. The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels. Therap Adv Gastroenterol. 2018;11:1756284818796956.
- Goncalves J, Santos M, Acurcio R, et al. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Aliment Pharmacol Ther. 2018;48(5):507–522.
- Park W, Lee SJ, Yun J, et al. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. Expert Rev Clin Immunol. 2015;11(Suppl 1):S25–31.
- Bui LA, Taylor C. Developing clinical trials for biosimilars. Semin Oncol. 2014;41(Suppl 1):S15–25.
- Afonso J, de Sousa HT, Rosa I, et al. Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays. Therap Adv Gastroenterol. 2017 Sep;10(9):661–671.
- Malíčková K, Ďuricová D, Bortlík M, et al. Serum trough infliximab levels: a comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. Biologicals. 2016 Jan;44(1):33–36.
- Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis. 2013 Mar;5(5):561–574.
- Rinaudo-Gaujous M, Paul S, Tedesco ED, et al. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther. 2013;38(8):914–924.
- Robert H. Saving money in the European healthcare systems with biosimilars. GaBI J. 2012;1:120–126.
- Castañeda-Hernández G, González-Ramírez R, Kay J, et al. Biosimilars in rheumatology: what the clinician should know. RMD Open. 2015;1(1):e000010.